Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including specialty, branded generics, generics, and APIs.

• Largest pharmaceutical company in India and 12th largest in the US generics market.

• 41 manufacturing facilities globally, with approvals from major regulators like USFDA.

• Over 43,000 employees worldwide, with a strong focus on R&D and quality compliance.

• Expanding presence in ex-US developed markets and emerging markets.

Financial performance and growth

• FY24 sales reached Rs 478 Bn, with a 10% YoY growth and 18% CAGR from FY09 to FY24.

• EBITDA margin at 26.9% and gross margin at 77.7% in FY24, reflecting strong profitability.

• Adjusted net profit margin at 21.1% in FY24, with ROCE at 18.2% and ROE at 16.7%.

• Market capitalization stood at US $51 Bn as of November 2024.

• Operating cash flow and free cash flow have shown consistent growth, with net cash from operations at Rs 121.5 Bn in FY24.

Revenue composition and business segments

• US formulations contributed 32%, India 31%, Emerging Markets 18%, Rest of World 14%, and API & Others 5% to FY24 sales.

• Specialty products accounted for over 18% of total sales in FY24, up from 7.3% in FY18.

• 26 specialty products marketed globally, with the US as the major contributor.

• India business leads with 8.1% market share and No.1 ranking in 13 doctor categories.

• Emerging Markets and Rest of World segments have strong local manufacturing and sales presence.